Open Access iconOpen Access

ARTICLE

CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

KAIWEN TIAN#, HANZHONG CHEN#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG*, JIUMIN LIU*

Department of Urology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China

* Corresponding Authors: YANLIN TANG. Email: email; JIUMIN LIU. Email: email
# Kaiwen Tian and Hanzhong Chen contributed equally to this work

(This article belongs to the Special Issue: Frontiers in cancer: tumor microenvironment)

BIOCELL 2024, 48(5), 817-834. https://doi.org/10.32604/biocell.2024.048737

Abstract

Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy and targeted therapy. Furthermore, to investigate the mechanism of this molecule’s influence on different biological behaviors of cells, cell tests in vitro have been conducted to observe the impact of its expression level. Results: CARD11 expression was upregulated which may be mainly modified by body methylation and was correlated with poor prognosis in ccRCC. In the tumor microenvironment of ccRCC, CARD11 expression was positively correlated with increased T lymphocyte infiltration and increased expression of inhibitory immune checkpoints. Moreover, ccRCC patients with high CARD11 expression had a better response to immunotherapy and targeted therapy. The knockdown of CARD11 ultimately suppressed the proliferation, migration, and invasion capabilities of ccRCC cells while simultaneously enhancing tumor cell apoptosis. Conclusion: We identified CARD11 as a novel therapeutic biomarker for immunotherapy and targeted therapy in ccRCC.

Graphical Abstract

CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

Keywords


Supplementary Material

Supplementary Material File

Cite This Article

APA Style
TIAN, K., CHEN, H., WANG, Q., JIANG, F., FENG, C. et al. (2024). CARD11 serves as a therapeutic biomarker for the drug therapies of ccrcc. BIOCELL, 48(5), 817-834. https://doi.org/10.32604/biocell.2024.048737
Vancouver Style
TIAN K, CHEN H, WANG Q, JIANG F, FENG C, LI T, et al. CARD11 serves as a therapeutic biomarker for the drug therapies of ccrcc. BIOCELL . 2024;48(5):817-834 https://doi.org/10.32604/biocell.2024.048737
IEEE Style
K. TIAN et al., "CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC," BIOCELL , vol. 48, no. 5, pp. 817-834. 2024. https://doi.org/10.32604/biocell.2024.048737



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 401

    View

  • 152

    Download

  • 0

    Like

Share Link